Home
    • Plans Blog Contact
    Pulse Biosciences Inc logo

    Pulse Biosciences Inc

    PLSE
    Last price US$30.21
    Market cap US$1.8b
    12M price change 103.16%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    West Pharmaceutical Services IncWST Industry peer Hologic IncHOLX Industry peer HaemoneticsHAE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Pulse Biosciences Inc Overview

    Industry: Medical Instruments & Supplies

    Sector: Healthcare

    Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue t Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Pulse Biosciences Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 04, 2026

    Quarterly result summary

    Revenue was $0.4M (reported). Net loss was -$0M.

    Revenue $0.4M reported
    Net loss -$0M reported

    What changed

    • Revenue reported to $0.4M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 10-Q May 14, 2026 SEC filing FORM 8-K May 04, 2026 SEC filing FORM 10-K/A Apr 30, 2026 Earnings release PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED FEBRUARY 19, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS Feb 19, 2026 SEC filing FORM 10-K Feb 19, 2026 SEC filing FORM 8-K Feb 19, 2026 SEC filing FORM 10-Q Nov 05, 2025 SEC filing FORM 8-K Nov 05, 2025 Earnings release PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED NOVEMBER 5, 2025 - BUSINESS UPDATES AND FINANCIAL RESULTS Nov 05, 2025 SEC filing FORM 10-Q Aug 12, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Pulse Biosciences Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Return on Equity

    Score 0.16/5
    Pulse Biosciences Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Pulse Biosci... PLSE US$1.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.27/5
    Pulse Biosciences Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Pulse Biosci... PLSE US$1.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Leverage

    Score 2.92/5
    Pulse Biosciences Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Pulse Biosci... PLSE US$1.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Pulse Biosciences Inc logo

    Pulse Biosciences Inc

    US$30.21

    US$1.8b

    5.33%

    103.16%